Wells Fargo & Company Tyra Biosciences, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 6,257 shares of TYRA stock, worth $100,487. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,257

Previous 6,506 3.83%

Holding current value

$100,487

Previous $104,000 41.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$16.7 - $24.36 $4,158 - $6,065	-249 Reduced 3.83%	6,257 $147,000
Q2 2024 Aug 13, 2024	BUY	$14.45 - $20.22 $25,735 - $36,011	1,781 Added 37.69%	6,506 $104,000
Q1 2024 May 10, 2024	BUY	$11.61 - $20.0 $7,569 - $13,040	652 Added 16.01%	4,725 $77,000
Q4 2023 Feb 09, 2024	BUY	$11.01 - $14.95 $9,281 - $12,602	843 Added 26.1%	4,073 $56,000
Q3 2023 Nov 13, 2023	SELL	$13.15 - $16.08 $30,008 - $36,694	-2,282 Reduced 41.4%	3,230 $44,000
Q2 2023 Aug 15, 2023	BUY	$11.99 - $17.51 $37,768 - $55,156	3,150 Added 133.36%	5,512 $93,000
Q1 2023 May 12, 2023	BUY	$6.85 - $16.22 $16,179 - $38,311	2,362 New	2,362 $37,000
Q3 2022 Nov 14, 2022	SELL	$6.61 - $12.42 $753 - $1,415	-114 Reduced 74.51%	39 $0
Q2 2022 Aug 12, 2022	SELL	$5.26 - $11.19 $12,671 - $26,956	-2,409 Reduced 94.03%	153 $1,000
Q1 2022 May 16, 2022	SELL	$10.03 - $14.09 $45,024 - $63,250	-4,489 Reduced 63.66%	2,562 $27,000
Q4 2021 Feb 14, 2022	BUY	$12.23 - $31.35 $86,233 - $221,048	7,051 New	7,051 $99,000

Others Institutions Holding TYRA

# of Institutions

Shares Held

43.5M

Call Options Held

353K

Put Options Held

1.1K

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $674M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Tyra Biosciences, Inc. Transaction History